Open Nav

Please submit your session questions in advance at

Synthetic Biologics, Inc.

  • Steven Shallcross,

Synthetic Biologics, Inc. (NYSE American: SYN) is a late-stage clinical company developing therapeutics that preserve the microbiome to protect and restore the health of patients. The Company's lead late-stage candidates are: (1) SYN-004 (ribaxamase) which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) beta-lactam antibiotics to prevent microbiome damage, C. difficile infection (CDI), overgrowth of pathogenic organisms and the emergence of antimicrobial resistance (AMR), and (2) SYN-010 which is intended to reduce the impact of methane producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). The Company’s preclinical pursuits include an oral formulation of the enzyme intestinal alkaline phosphatase (IAP) to treat both local GI and systemic diseases as well as monoclonal antibody therapies for the prevention and treatment of pertussis.

  • Date:Monday, February 11
  • Time:10:45 AM - 11:00 AM
  • Room:Herald/Soho
  • Location:7th Floor
  • Session Type:Company Presentation
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:23511
  • Goal for Presentation:Business Development & Investor Awareness
  • Company
  • Company HQ City:Rockville
  • Company HQ State:Maryland
  • Company HQ Country:United States
  • Market Cap:$10 M
  • Ticker:SYN
  • Exchange:NYSE American
  • CEO/Top Company Official:Steven Shallcross
  • Year Founded:2008
  • Main Therapeutic Focus:Gastrointestinal
  • Lead Product in Development:SYN-004 (ribaxamase) designed to prevent antibiotic-mediated gut microbiome damage, C. diff and AMR
  • Development Phase of Primary Product:Phase III
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):4
  • Additional Information/Comments:The Company's second lead program is SYN-010, a proprietary, modified-release formulation of lovastatin lactone that is intended to reduce methane production by certain microorganisms (M. smithii) in the gut while minimizing disruption to the microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C). A Phase 2b investigator-sponsored clinical study is ongoing and being conducted by the Medically Associated Science and Technology Program at Cedars-Sinai Medical Center. The study comprises a 12-week, placebo-controlled, double-blind, randomized clinical trial to evaluate two dose strengths of oral SYN-010 (21 mg and 42 mg) in approximately 150 patients diagnosed with IBS-C. A data readout from this investigator-sponsored clinical study is expected during the second half of 2019.
Steven Shallcross